Jia Liu, PhD
University of Arkansas for Medical Sciences
College of Medicine
Microbiology & Immunology
Cancer Research Interest
- Research Interest Statement: The focus of Dr. Jia Liu's research is to use the knowledge of the coordinated host intrinsic and innate immunity for thedevelopment of cancer immunotherapy. I use myxoma virus (MYXV), a poxvirus only causing infectious disease in rabbitsas the model organism; particularly I study the immunosuppressive tumor environment such as the one presented inovarian cancer (OC) and repurpose oncolytic MYXV for immunotherapy of OC. In this process our work also provide in depthunderstanding of the immunosuppressive tumor environment. We discovered an unusual STAT3 signaling pathway thatplays a critical role for the immunosuppressive myeloid and tumor cells. By using immunotherapeutic MYXV to disarmthese disease myeloid and tumor cells, we aim to provide novel treatment options for cancer patients.Our long-term goal is to improve understanding the cross talk between host intrinsic and innate immunity, so that itsactivation can be applied to facilitate the elimination of malignancy through immunotherapy.
- Email Address: JLIU4@UAMS.EDU
- Profiles Research Networking Software: View Profile
- NIH/Nat. Inst. of General Medical Sciences – 1P30GM145393“COBRE - Phase III Center for Microbial Pathogenesi”Co-Investigator05/05/22 – 04/30/27
- NIH/Nat. Inst. of General Medical Sciences – 1P30GM145393“COBRE - Phase III”Co-Investigator05/05/22 – 04/30/27
- NIH/Nat. Inst. of Allergy & Infectious Diseases – 1R01AI139106“Studies in Poxvirus Evasion of SAMD9 Pathway”Principal Investigator01/01/19 – 12/31/23
- LaFargue CJ, Amero P, Noh K, [et al., including Liu J]. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nature communications. 2023 14(1):2407. PMID: 37100807. PMCID: PMC10133315.
- Corken A, Ware J, Dai J, [et al., including Liu J]. Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study. Kidney360. 2022 3(12):2036-2047. PMID: 36591354. PMCID: PMC9802560.
- Campos S, Matulonis U, Berlin S, [et al., including Liu J]. A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. International journal of clinical oncology. 2022 27(12):1881-1890. PMID: 36344654.
- Conrad SJ, Raza T, Peterson EA, [et al., including Liu J]. Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages. PLoS pathogens. 2022 18(9):e1010316. PMID: 36103568. PMCID: PMC9473615.
- Li D, Yu X, Kottur J, [et al., including Liu J]. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022. PMID: 35525905. PMCID: PMC9189076.
- Araujo N, Sledziona J, Noothi SK, [et al., including Liu J]. Tumor Suppressor Par-4 Regulates Complement Factor C3 and Obesity. Frontiers in oncology. 2022 12:860446. PMID: 35425699. PMCID: PMC9004617.
- Arthur JM, Forrest JC, Boehme KW, [et al., including Liu J]. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PloS one. 2021 16(9):e0257016. PMID: 34478478. PMCID: PMC8415618.
- Wang R, Kumar B, Bhat-Nakshatri P, [et al., including Liu J]. Aging-associated skeletal muscle defects in HER2/Neu transgenic mammary tumor model. JCSM rapid communications. 2021 4(1):24-39. PMID: 33842876. PMCID: PMC8028024.
- Tang B, Guo ZS, Bartlett DL, [et al., including Liu J]. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 26(9):2216-2230. PMID: 32019860. PMCID: PMC7723446.
- Esteves PJ, Abrantes J, Baldauf HM, [et al., including Liu J]. Author Correction: The wide utility of rabbits as models of human diseases. Experimental & molecular medicine. 2019 51(7):71. PMID: 31270317. PMCID: PMC6802666.
- Conrad SJ, Liu J. Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes. Methods in molecular biology (Clifton, N.J.). 2019 1937:189-209. PMID: 30706397. PMCID: PMC6855597.
- Tang B, Guo ZS, Bartlett DL, [et al., including Liu J]. A cautionary note on the selectivity of oncolytic poxviruses. Oncolytic virotherapy. 2019 8:3-8. PMID: 30805315. PMCID: PMC6375109.
- Esteves PJ, Abrantes J, Baldauf HM, [et al., including Liu J]. The wide utility of rabbits as models of human diseases. Experimental & molecular medicine. 2018 50(5):1-10. PMID: 29789565. PMCID: PMC5964082.
- Deng BQ, Luo Y, Kang X, [et al., including Liu JY]. Epoxide metabolites of arachidonate and docosahexaenoate function conversely in acute kidney injury involved in GSK3? signaling. Proceedings of the National Academy of Sciences of the United States of America. 2017 114(47):12608-12613. PMID: 29109264. PMCID: PMC5703276.
- Nounamo B, Liem J, Cannon M, Liu J. Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer InÂ Vitro and in a Syngeneic Murine Dissemination Model. Molecular therapy oncolytics. 2017 6:90-99. PMID: 28875159. PMCID: PMC5573804.
- Nounamo B, Li Y, O'Byrne P, [et al., including Liu J]. An interaction domain in human SAMD9 is essential for myxoma virus host-range determinant M062 antagonism of host anti-viral function. Virology. 2017 503:94-102. PMID: 28157624. PMCID: PMC5419587.
- Liem J, Liu J. Stress Beyond Translation: Poxviruses and More. Viruses. 2016 8(6). PMID: 27314378. PMCID: PMC4926189.